学术成果 - 赛诺哈勃药业（成都）有限公司

技术平台与管线

学术成果产品管线技术平台

首页>技术平台与管线 >学术成果

2026-03-17

Optimization of Dosing Regimens for Plasminogen Activation Inhibitor BT-114143 Using a Small Molecule TMDD Population PK and PD Model in Healthy Subjects

European journal of drug metabolism and pharmacokinetics vol. 51,2 (2026): 217-228. doi:10.1007/s13318-026-00987-2
2025-09-26

Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life

EJNMMI Radiopharm Chem. 2025 Sep 26;10(1):61. doi: 10.1186/s41181-025-00385-0.
2025-04-21

Preclinical evaluation of SNH-110: A potent, selective, next-generation RET inhibitor overcoming adaptive drug resistances

Cancer Res 15 April 2025; 85 (8_Supplement_1): 5611. https://doi.org/10.1158/1538-7445.AM2025-5611
2025-03-27

Discovery of BT-114143, a Novel and Potent Phosphoric Acid-Containing Small-Molecule Plasminogen Activation Inhibitor for Hyperfibrinolysis

Journal of medicinal chemistry vol. 68,6 (2025): 6084-6099. doi:10.1021/acs.jmedchem.4c03190
2025-03-21

Enteral Delivery Of Novel Plasminogen Inhibitors For The Prevention Of Abdominal Adhesions Following Surgery In An Experimental Rat Model

IARS | International Anesthesia Research Society 2025.3.21
2023-11-02

Discovery of BT-114143, a Novel and Potent Small-Molecule Plasminogen Inhibitor for Hyperfibrinolysis

Blood Volume 142, Supplement 1, 2 November 2023, Page 1229. https://doi.org/10.1182/blood-2023-185454

加载更多

联系我们

028-85911582转6866

四川省成都市高新区和祥三街263号

版权所有 © 2002-2021 赛诺哈勃药业（成都）有限公司保留所有权利备案号：蜀ICP备2021033182号-1